Cargando…
Matrine in association with FD-2 stimulates F508del-cystic fibrosis transmembrane conductance regulator activity in the presence of corrector VX809
Cystic fibrosis is caused by mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, and the predominant mutation is termed Phe508del (F508del). Therapy for F508del-CFTR patients is based on the use of Orkambi(®), a combination of VX809 and VX770. However, though Orkambi le...
Autores principales: | Marengo, Barbara, Speciale, Andrea, Senatore, Lisa, Garibaldi, Silvano, Musumeci, Francesca, Nieddu, Erika, Pollarolo, Benedetta, Pronzato, Maria Adelaide, Schenone, Silvia, Mazzei, Mauro, Domenicotti, Cinzia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779973/ https://www.ncbi.nlm.nih.gov/pubmed/29039559 http://dx.doi.org/10.3892/mmr.2017.7736 |
Ejemplares similares
-
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays
por: Parodi, Alice, et al.
Publicado: (2022) -
Vx-809, a CFTR Corrector, Acts through a General Mechanism of Protein Folding and on the Inflammatory Process
por: Pecoraro, Michela, et al.
Publicado: (2023) -
Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells
por: Stanton, Bruce A., et al.
Publicado: (2015) -
Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR
por: Farinha, Carlos M, et al.
Publicado: (2015) -
High-Content Surface and Total Expression siRNA Kinase
Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance
F508del-CFTR Rescue
por: Perkins, Lydia A., et al.
Publicado: (2018)